Asunto(s)
Tratamiento Farmacológico de COVID-19 , COVID-19/diagnóstico , Coinfección/diagnóstico , Coinfección/tratamiento farmacológico , Hepatitis Viral Humana/diagnóstico , Hepatitis Viral Humana/tratamiento farmacológico , COVID-19/virología , Coinfección/virología , Hepatitis Viral Humana/virología , Humanos , Masculino , Tamizaje Masivo/métodos , Pandemias , SARS-CoV-2/efectos de los fármacosAsunto(s)
Carcinoma Hepatocelular/epidemiología , Carcinoma Hepatocelular/virología , Hepatitis B Crónica/complicaciones , Hepatitis C Crónica/complicaciones , Neoplasias Hepáticas/epidemiología , Neoplasias Hepáticas/virología , Adolescente , Adulto , África/epidemiología , Edad de Inicio , Anciano , Anciano de 80 o más Años , Carcinoma Hepatocelular/diagnóstico , Niño , Coinfección/complicaciones , Coinfección/diagnóstico , Femenino , Hepatitis B Crónica/diagnóstico , Hepatitis C Crónica/diagnóstico , Humanos , Neoplasias Hepáticas/diagnóstico , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality and has an increasing incidence worldwide. HCC can be induced by multiple etiologies, is influenced by many risk factors, and has a complex pathogenesis. Furthermore, HCCs exhibit substantial heterogeneity, which compounds the difficulties in developing effective therapies against this highly lethal cancer. With advances in cancer biology and molecular and genetic profiling, a number of different mechanisms involved in the development and progression of HCC have been identified. Despite the advances in this area, the molecular pathogenesis of hepatocellular carcinoma is still not completely understood. This review aims to elaborate our current understanding of the most relevant genetic alterations and molecular pathways involved in the development and progression of HCC, and anticipate the potential impact of future advances on therapeutic drug development.